摘要
目的探讨晚期食管癌治疗中应用免疫治疗的临床疗效及安全性。方法选取2020年7月—2022年12月滕州市工人医院接受化疗和免疫治疗(选用卡瑞利珠单抗)的晚期食管癌患者78例。随机将患者分为化疗组(n=31,白蛋白紫杉醇+顺铂化疗)与联合治疗组(n=47,卡瑞利珠单抗联合白蛋白紫杉醇+顺铂化疗)。对比2组患者的无进展生存期(progression-free-survival,PFS)、总生存期(overall survival,OS)、客观缓解率(objective response rate,ORR)、疾病控制率(disease control rate,DCR)及常见不良反应等情况,并开展各项指标数据的分析和对比。结果患者平均随访时间为(15.70±0.32)个月。化疗组客观缓解率(22.58%)与疾病控制率(48.39%)低于联合治疗组(46.81%、53.19%),差异有统计学意义(P<0.05)。联合治疗组不良反应发生率(32.26%)低于化疗组(64.52%),差异有统计学意义(P<0.05)。结论在晚期食管癌患者的治疗中应用免疫治疗可延长生存期,并且患者耐受性良好。此文的研究结果为免疫治疗在晚期食管癌后期标准制定提供了借鉴内容。
Objective To explore the clinical efficacy and safety of immunotherapy in the treatment of advanced esophageal cancer.Methods A total of 78 patients with advanced esophageal cancer who received chemotherapy and immunotherapy(using carrilizumab)in Tengzhou Workers'Hospital from July 2020 to December 2022 were included.All patients were randomly divided into a chemotherapy group(n=31,albumin paclitaxel+cisplatin chemotherapy)and a combination therapy group(n=47,calilizumab combined with albumin paclitaxel+cisplatin chemotherapy).Progression-free survival(PFS),overall survival(OS)and objective response rate were compared between the two groups.ORR,disease control rate(DCR),common adverse reactions,etc.,and analyzed and compared the data of various indicators.Results The mean follow-up time was(15.70±0.32)months.The objective response rate(22.58%)and disease control rate(48.39%)in the chemotherapy group were lower than those in the combined treatment group(46.81%and 53.19%),and the difference was statistically significant(P<0.05).The ratio of adverse reactions between the two groups showed that the incidence of adverse reactions in combined treatment group(32.26%)was lower than that in chemotherapy group(64.52%),and the difference was statistically significant(P<0.05).Conclusion In the treatment of patients with advanced esophageal cancer,the application of immunotherapy can prolong the survival period,and the patients are well tolerated.Meanwhile,the study results of this paper provide reference content for the formulation of the standard of immunotherapy in the later stage of advanced esophageal cancer.
作者
吕春燕
杨潇
赵亮
LYU Chunyan;YANG Xiao;ZHAO Liang(Department of Oncology,Tengzhou Workers'Hospital,Tengzhou Shandong 277500,China;Department of Orthopaedics,Tengzhou Workers'Hospital,Tengzhou Shandong 277500,China)
出处
《中国卫生标准管理》
2024年第5期128-131,共4页
China Health Standard Management
